Related Experiment Video
Updated: Jul 7, 2026
09:43
Hand-held Clinical Photoacoustic Imaging System for Real-time Non-invasive Small Animal Imaging
Published on: October 16, 2017
High-resolution, hand-held camera for sentinel-node detection.
Francesco Scopinaro1, Anna Tofani, Gianpaolo di Santo
1Department of Radiological Sciences, La Sapienza University, Rome, Italy. francesco.scopinaro@uniroma1.it
Cancer Biotherapy & Radiopharmaceuticals
|February 27, 2008
Summary
This study shows that using an imaging probe (IP) for breast cancer sentinel node (SN) biopsy is faster and identifies more SNs and invasions compared to traditional Anger camera lymphoscintigraphy (ACL). The IP significantly improves detection rates and reduces procedure time.
Area of Science:
- Oncology
- Medical Imaging
- Surgical Oncology
Background:
- The imaging probe (IP) is a high-resolution, handheld gamma camera.
- Sentinel node (SN) biopsy is crucial for breast cancer staging.
Purpose of the Study:
- To evaluate the efficacy of an imaging probe (IP) in detecting breast cancer sentinel nodes (SNs).
- To compare the performance of IP combined with a gamma probe (GP) against standard Anger camera lymphoscintigraphy (ACL) for SN biopsy.
Main Methods:
- 120 T1 breast cancer patients were divided into two matched subgroups (n=60 each).
- Subgroup A (SA) used a standard gamma probe (GP) for SN detection.
- Subgroup B (SB) used the imaging probe (IP) plus GP for SN detection.
Main Results:
- SB identified significantly more SNs (105 vs. 82) and more patients with positive nodes (25% vs. 21.6%) than SA.
- SB demonstrated a reduced SN withdrawal time (7.4 min vs. 11.25 min) compared to SA.
- SB detected more nodal invasions, including on second and third nodes, compared to SA.
Conclusions:
- SN biopsy using the imaging probe (IP) is a faster and more effective method for detecting breast cancer sentinel nodes.
- The IP enhances the identification of SNs and metastatic invasions, outperforming traditional ACL.
- This advanced imaging technique improves diagnostic yield in breast cancer staging.
